MedTrace Logo

RSHF in Colorectal Cancer

NCT01220063 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-01-07

No results posted yet for this study

Summary

The purpose of this study is to study stereotactic radiotherapy with a dose of 40 Gy in 4 fractions over 2 weeks with concomitant 40 mg/m2 of irinotecan (1st and 3rd irradiation session).

Conditions

Interventions

RADIATION

Radiation

10 Gy for 4 times (total 40 Gy)

DRUG

Irinotecan

40 mg/m² : Day 1 and day 8

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • RIO EMMANUEL, MD · INSTITUT DE CANCEROLOGIE DE L'OUEST

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-19
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01220063 on ClinicalTrials.gov